bioAffinity Technologies, Inc. filed a Form S-1 registration statement for an initial public offering on 2024-09-11. It has amended it 4 times. It filed its final prospectus on 2026-06-18, at a public offering price of $0.80 per share. Each fact below is quoted from the filing named with it.
What the filings say
Listing
Our common stock is listed on The Nasdaq Capital Market under the symbol “BIAF”.From the 424B4 filed 2026-06-18
Shares offered
We are offering 1,040,000 shares of our common stock, par value $0.007 per share at a public offering price of $0.80 per share.From the 424B4 filed 2026-06-18
Offering price
We are offering 1,040,000 shares of our common stock, par value $0.007 per share at a public offering price of $0.80 per share.From the 424B4 filed 2026-06-18
Use of proceeds
We intend to use the net proceeds from this offering for working capital and general corporate purposes.From the 424B4 filed 2026-06-18
Revenue
During the three months ended March 31, 2026, we generated revenue of approximately $1.4 million, and $6.2 million and $9.4 million during the years ended December 31, 2025, and December 31, 2024, respectively.From the S-1 filed 2026-06-12
Net loss or income
For the year 2024, cash used in operations was $7.1 million and net loss was $9.0 million.From the S-1/A filed 2025-05-05
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-09-11 | Registration statement filed | S-1 |
| 2024-11-27 | Registration statement filed | S-1 |
| 2025-04-11 | Registration statement filed | S-1 |
| 2025-05-02 | Registration statement filed | S-1 |
| 2025-05-05 | Registration statement amended | S-1/A |
| 2025-05-07 | Final prospectus filed: the offering is priced | 424B4 |
| 2025-08-29 | Registration statement filed | S-1 |
| 2025-09-15 | Registration statement amended | S-1/A |
| 2025-09-24 | Registration statement filed | S-1 |
| 2025-09-25 | Registration statement amended | S-1/A |
| 2025-09-30 | Final prospectus filed: the offering is priced | 424B4 |
| 2026-04-30 | Registration statement filed | S-1 |
| 2026-06-12 | Registration statement filed | S-1 |
| 2026-06-16 | Registration statement amended | S-1/A |
| 2026-06-18 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for bioAffinity Technologies, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.